Neuropsychiatric Disorders and Treatment Market Size, Share, and Industry Analysis, By Drug Class (Cholinesterase Inhibitors, Anticonvulsants, GABAergics, Opioid Antagonist, Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-norepinephrine Reuptake Inhibitors (SNRIs), and Others), By Route of Administration (Oral and Parenteral), By Application (Neurodegenerative Diseases, Seizures, Sleep Disorders, Eating Disorders, Cognitive Deficit Disorders, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction
   1. Research Scope
   2. Market Segmentation
   3. Research Methodology
   4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
   1. Market Drivers
   2. Market Restraints
   3. Market Opportunities
   4. Market Trends
4. Key Insights
   1. Prevalence of Key Diseases, By Key Countries, 2023
   2. New Product Approval/ Launches, By Key Players
   3. Pipeline Analysis, By Key Players
   4. Overview: Regulatory Overview, By Key Countries
   5. Key Industry Developments (Acquisitions, Mergers, Partnerships, etc.)
   6. Impact of COVID-19 on the Market
5. Global Neuropsychiatric Disorders and Treatment Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights, and Forecast – By Drug Class
      1. Cholinesterase Inhibitors
      2. Anticonvulsants
      3. GABAergic
      4. Opioid Antagonist
      5. Selective Serotonin Reuptake Inhibitors (SSRIs)
      6. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
      7. Others
   2. Market Analysis, Insights, and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
   3. Market Analysis, Insights, and Forecast – By Indication
      1. Neurodegenerative Diseases
      2. Seizures
      3. Sleep Disorders
      4. Eating Disorders
      5. Cognitive Deficit Disorders
      6. Others
   4. Market Analysis, Insights, and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   5. Market Analysis, Insights, and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
6. North America Neuropsychiatric Disorders and Treatment Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights, and Forecast – By Drug Class
      1. Cholinesterase Inhibitors
      2. Anticonvulsants
      3. GABAergic
      4. Opioid Antagonist
      5. Selective Serotonin Reuptake Inhibitors (SSRIs)
      6. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
      7. Others
   2. Market Analysis, Insights, and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
   3. Market Analysis, Insights, and Forecast – By Indication
      1. Neurodegenerative Diseases
      2. Seizures
      3. Sleep Disorders
      4. Eating Disorders
      5. Cognitive Deficit Disorders
      6. Others
   4. Market Analysis, Insights, and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   5. Market Analysis, Insights, and Forecast – By Country
      1. U.S.
      2. Canada
7. Europe Neuropsychiatric Disorders and Treatment Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights, and Forecast – By Drug Class
      1. Cholinesterase Inhibitors
      2. Anticonvulsants
      3. GABAergic
      4. Opioid Antagonist
      5. Selective Serotonin Reuptake Inhibitors (SSRIs)
      6. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
      7. Others
   2. Market Analysis, Insights, and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
   3. Market Analysis, Insights, and Forecast – By Indication
      1. Neurodegenerative Diseases
      2. Seizures
      3. Sleep Disorders
      4. Eating Disorders
      5. Cognitive Deficit Disorders
      6. Others
   4. Market Analysis, Insights, and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   5. Market Analysis, Insights, and Forecast – By Country/Sub-Region
      1. Germany
      2. U.K.
      3. France
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
8. Asia Pacific Neuropsychiatric Disorders and Treatment Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights, and Forecast – By Drug Class
      1. Cholinesterase Inhibitors
      2. Anticonvulsants
      3. GABAergic
      4. Opioid Antagonist
      5. Selective Serotonin Reuptake Inhibitors (SSRIs)
      6. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
      7. Others
   2. Market Analysis, Insights, and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
   3. Market Analysis, Insights, and Forecast – By Indication
      1. Neurodegenerative Diseases
      2. Seizures
      3. Sleep Disorders
      4. Eating Disorders
      5. Cognitive Deficit Disorders
      6. Others
   4. Market Analysis, Insights, and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   5. Market Analysis, Insights, and Forecast – By Country/Sub-Region
      1. China
      2. India
      3. Japan
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
9. Latin America Neuropsychiatric Disorders and Treatment Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights, and Forecast – By Drug Class
      1. Cholinesterase Inhibitors
      2. Anticonvulsants
      3. GABAergic
      4. Opioid Antagonist
      5. Selective Serotonin Reuptake Inhibitors (SSRIs)
      6. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
      7. Others
   2. Market Analysis, Insights, and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
   3. Market Analysis, Insights, and Forecast – By Indication
      1. Neurodegenerative Diseases
      2. Seizures
      3. Sleep Disorders
      4. Eating Disorders
      5. Cognitive Deficit Disorders
      6. Others
   4. Market Analysis, Insights, and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   5. Market Analysis, Insights and Forecast – By Country/Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
10. Middle East & Africa Neuropsychiatric Disorders and Treatment Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights, and Forecast – By Drug Class
       1. Cholinesterase Inhibitors
       2. Anticonvulsants
       3. GABAergic
       4. Opioid Antagonist
       5. Selective Serotonin Reuptake Inhibitors (SSRIs)
       6. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
       7. Others
    2. Market Analysis, Insights, and Forecast – By Route of Administration
       1. Oral
       2. Parenteral
    3. Market Analysis, Insights, and Forecast – By Indication
       1. Neurodegenerative Diseases
       2. Seizures
       3. Sleep Disorders
       4. Eating Disorders
       5. Cognitive Deficit Disorders
       6. Others
    4. Market Analysis, Insights, and Forecast – By Distribution Channel
       1. Hospital Pharmacies
       2. Retail Pharmacies
       3. Online Pharmacies
    5. Market Analysis, Insights and Forecast – By Country/Sub-Region
       1. South Africa
       2. GCC
       3. Rest of Middle East & Africa
11. Competitive Analysis
    1. Global Market Share Analysis (2023)
    2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
       1. Novartis AG
       2. Biogen Inc.
       3. H. Lundbeck A/S
       4. Otsuka Pharmaceutical Co., Ltd.
       5. Pfizer, Inc.
       6. Hoffmann-La Roche Ltd
       7. Merck & Co., Inc.
       8. Novartis AG
       9. Sanofi
       10. Teva Pharmaceutical Industries Ltd.
       11. Other Prominent Players